Novartis leads way in Big Pharma growth, which is expected to be 4%
Swiss drug major Novartis is forecast to deliver the strongest prescription pharmaceutical sales growth of any Big Pharma company over the period 2009-15, based on organic performance, finds independent market analyst Datamonitor.
The company is expected to deliver a compound annual growth rate (CAGR) of over 4% which would add more than $10 billion to sales. Over the same period Datamonitor is forecasting an average of just 1.4% CAGR for Big Pharma generally.
Simon King, PharmaVitae analyst at Datamonitor, said: 'Integral to Novartis delivering a sales growth performance well above average is the company's heavily diversified prescription pharmaceutical offering.'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze